Option Care Health Inc logo

Option Care Health Inc(OPCH)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 28 days
PROFIT SINCE LAST BUY
+2.13% ▲
LAST CLOSE
$31.71
11/16/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for OPCH

11/16/2026: OPCH (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Option Care Health Inc is a prominent US-listed healthcare services company specializing in home and alternate-site infusion therapies. The company's primary strength lies in its extensive nationwide clinical network and robust partnerships with major health systems. Its core investment narrative centers on secular demographic tailwinds driving demand for cost-effective care outside traditional hospitals. However, the company faces key risks regarding third-party reimbursement pressures and intense competition from integrated healthcare giants. Overall, the stock suits growth-oriented investors monitoring healthcare delivery developments, while lacking dividend yield for income strategies.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company demonstrates consistent multi-year revenue expansion driven by secular tailwinds in home healthcare.
Momentum investorStrong fit while signal remains positiveFavorable transaction news and steady top-line results support positive near-term price momentum.
Value investorMixed fitValuation multiples reflect steady healthcare sector pricing relative to projected earnings growth.
Dividend investorWeak fitThe company does not pay a cash dividend, focusing instead on capital reinvestment.
Low-risk investorMixed fitWhile healthcare demand is defensive, regulatory and reimbursement uncertainties introduce moderate risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumStock prices fluctuate based on broader market sentiment and healthcare policy developments.
Valuation riskMediumMultiples can compress if earnings growth rates moderate relative to expectations.
Competition risk (Pharmacy benefit managers and health conglomerates)Medium / highCompetition from large integrated health networks and pharmacy providers can pressure margins.
Business qualityStrongThe company maintains an established clinical framework and a leading independent market footprint.
Dividend incomeLow / noneNo regular dividend payments are distributed to shareholders.
Execution riskMediumSuccessful scaling depends on managing clinical labor pools and maintaining high service quality across national operations.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.74B USD
Price to earnings Ratio 22.93
1Y Target Price 30.03
Price to earnings Ratio 22.93
1Y Target Price 30.03
Volume (30-day avg) 6.4M shares
Beta 0.46
52 Weeks Range 18.01 - 36.80
Updated Date 11/16/2026
52 Weeks Range 18.01 - 36.80
Updated Date 11/16/2026
Dividends yield (FY) -
Basic EPS (TTM) 1.38

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
63.9%
Active BUY / eligible
69 / 108
30-Day BUY Count Change
+31
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Care Facilities

BUY participation
87.5%
Active BUY / eligible
7 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Flat / Range-Bound
PRICE PATH

Flat / Range-Bound

The stock price has been trading within a narrow range with minimal directional movement.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 9.69%
Avg. Invested days 51
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/16/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
OPCH receives a 3-star rating, supported by solid quantitative characteristics. The rating is constrained by soft unit economics, weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
OPCH has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid revenue growth (+13.0%) is partially offset by slightly negative earnings growth (-2.0%), soft cash generation (FCF margin 3.8%), soft profitability (net margin 3.7%).

Financial Health Rating

★★★★★
OPCH's financial health is supported by solid cash strength, including free-cash-flow generation (3.8% of revenue). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is OPCH's strongest growth driver at +13.0% FY2025 versus FY2024 (solid, 4 stars). By comparison, while earnings growth (-2.0%, slightly negative) and free-cash-flow growth (-24.5%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 110.3% and approximately 98.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 1.63% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 14.76%
Wellington Management Company LLP 7.87%
Vanguard Portfolio Management, LLC 5.52%
Fuller & Thaler Asset Management Inc 4.97%
Vanguard Capital Management, LLC 4.72%

Unit Economics (Per $1K Revenue)

★★★★★
OPCH generates approximately $181 of gross profit, $60 of operating income, and $38 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Soft margins explain the 2-star rating, with moderate cash conversion and moderate capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 26.62%

Quantitative Style Profile

★★★★★
OPCH has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Infusion ServicesReimbursements from commercial insurance, Medicare, and Medicaid for administering complex drug therapies in home or alternate-site settings.The company generates revenue by providing essential medical treatments directly to patients outside of traditional hospitals.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-04
When Before Market
Estimate 0.44
Actual 0.44

Profitability

Profit Margin 3.74%
Operating Margin (TTM) 5.88%

Management Effectiveness

Return on Assets (TTM) 6.08%
Return on Equity (TTM) 16.04%

Valuation

Trailing PE 22.93
Forward PE 14.93
Enterprise Value 5.71B
Price to Sales(TTM) 0.82
Enterprise Value 5.71B
Price to Sales(TTM) 0.82
Enterprise Value to Revenue 0.99
Enterprise Value to EBITDA 13.54
Shares Outstanding 149.80M
Shares Floating 147.93M
Shares Outstanding 149.80M
Shares Floating 147.93M
Percent Insiders 1.63
Percent Institutions 110.34

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.